Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Successful treatment of recalc...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus

Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus

Bibliographic Details
Main Authors: Bishoy Abdelmalik, BS, Steven Svoboda, MD, Pooja Gurnani, MD, Kiran Motaparthi, MD
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:JAAD Case Reports
Subjects:
anifrolumab
lupus
recalcitrant
refractory
Online Access:http://www.sciencedirect.com/science/article/pii/S2352512624004569
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2352512624004569

Similar Items

  • Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and DLE (discoid lupus erythematosus)
    by: E. Parriel, et al.
    Published: (2025-03-01)
  • Anifrolumab for the treatment of refractory chilblain lupus erythematosus
    by: Michael J. Woodbury, BS, et al.
    Published: (2024-06-01)
  • Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature
    by: Giovanni Paolino, et al.
    Published: (2023-10-01)
  • An update on the management of refractory cutaneous lupus erythematosus
    by: Alice Verdelli, et al.
    Published: (2022-09-01)
  • Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
    by: Kyriakos A. Kirou, et al.
    Published: (2022-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs